REG - Polarean Imaging PLC - Block listing six monthly return

Polarean ImagingAnnouncement

27/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230127:nRSa0081Oa&default-theme=true

RNS Number : 0081O  Polarean Imaging PLC  27 January 2023

 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Block Listing Six Monthly Return

 

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company
today makes the following notification pursuant to Schedule Six of the AIM
Rules for Companies regarding its existing block admission arrangements:

 

 Name of applicant:                                                                     Polarean Imaging Plc
 Name of scheme:                                                                        Polarean Share Option Plan
 Number and class of securities originally admitted:                                    8,000,000 ordinary shares of £0.00037 each
 Date of admission:                                                                     29 July 2021
 Period of return:                                         From:                        28 July 2022     To:              26 January 2023
 Balance of unallotted securities under scheme(s) from previous return:                 4,025,657
 Plus: The amount by which the block scheme(s) has been increased since the             0
 date of the last return (if any increase has been applied for):

 Less: Number of securities issued/allotted under scheme(s) during period (see          0
 LR3.5.7G):

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:              4,025,657
 Total number of securities in issue at the end of the period                           213,047,509

 

 Name of contact:              Richard Hullihen, Chief Executive Officer
 Telephone number of contact:  + 44 (0)20 7933 8780 or  polarean@walbrookpr.com

 

 

 

 

Enquiries:

 

 Polarean Imaging plc                                     www.polarean.com (http://www.polarean.com) / www.polarean-ir.com
                                                          (http://www.polarean-ir.com)
 Richard Hullihen, Chief Executive Officer                Via Walbrook PR
 Kenneth West, Chairman

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                 +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment
 Banking)
 Nick Adams / Nick Harland (Corporate Broking)

 Walbrook PR        Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
                    (mailto:polarean@walbrookpr.com)
 Anna Dunphy /Phillip Marriage         Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com (http://www.polarean.com) )

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the
"Group") are revenue-generating, medical imaging technology companies
operating in the high-resolution medical imaging space.  Polarean aspires to
revolutionize pulmonary medicine by bringing the power and safety of MRI to
the respiratory healthcare community in need of new solutions to evaluate lung
function, diagnose disease, characterize disease progression, and monitor
response to treatment. By researching, developing, and commercializing novel
imaging solutions with a non-invasive and radiation-free functional imaging
platform, Polarean's vision is to help address the global unmet medical needs
of more than 500 million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarization science and
has successfully developed the first and only hyperpolarized MRI contrast
agent to be approved in the United States. On December 23, 2022, the FDA
granted approval for Polarean's first drug device combination product,
XENOVIEW(TM) (xenon Xe 129 hyperpolarized). (129)Xe MRI is also currently
being studied for visualization and quantification of gas exchange regionally
in the smallest airways of the lungs, across the alveolar tissue membrane, and
into the pulmonary bloodstream for future clinical indications.

 

XENOVIEW(TM) is a trademark of Polarean, Inc.
 
POL-PR-2201

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRNKABQNBKDFDB